RxSight (NASDAQ:RXST) Announces Quarterly Earnings Results

RxSight (NASDAQ:RXST) issued its quarterly earnings results on Wednesday. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.25) by $0.22, FiscalAI reports. RxSight had a negative net margin of 25.15% and a negative return on equity of 12.82%. RxSight’s revenue for the quarter was down 18.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.03 EPS.

Here are the key takeaways from RxSight’s conference call:

• Q4 2025 sales were $32.6M, down 19% year‑over‑year driven by a sharp decline in LDD placements; the company reported a Q4 net loss of $9.2M and full‑year LDD revenue fell ~48% versus 2024.
• 2026 guidance is for $120M–$135M in revenue (about a 5% decline at the midpoint) with a lower gross‑margin guide of 70%–72% due to higher‑cost inventory and manufacturing variances, and operating expenses of $150M–$160M (including $30M–$32M of stock‑based comp).
• LAL momentum improved sequentially in Q4 (28,611 LALs sold, generating $28.2M) and LALs comprised an all‑time high 86% of sales; the company exited 2025 with a 1,134 LDD installed base (up 17% YoY) and is focused on driving utilization within that base.
• Clinical validation is strengthening—post‑approval study data accepted for publication showed 93% of LALs within 0.5D of target, supported by a >20,000‑eye registry presentation—while RxSight continues active R&D with multiple approvals and planned submissions.
• International expansion is deliberate and expected to contribute only modestly in 2026 as the company builds local KOLs and country‑specific data (approvals in EU/UK/SE Asia/Australia in place; China and Japan are in progress), targeting more meaningful revenue in 2027+.

RxSight Price Performance

NASDAQ RXST traded down $0.13 during trading hours on Wednesday, reaching $8.81. 903,277 shares of the company’s stock traded hands, compared to its average volume of 1,072,171. RxSight has a 52-week low of $6.32 and a 52-week high of $29.69. The firm has a 50-day simple moving average of $9.53 and a 200 day simple moving average of $9.49. The firm has a market cap of $362.27 million, a PE ratio of -10.01 and a beta of 1.14.

Institutional Trading of RxSight

Several institutional investors have recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in shares of RxSight by 6.0% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,861 shares of the company’s stock worth $552,000 after purchasing an additional 1,232 shares in the last quarter. Invesco Ltd. lifted its holdings in shares of RxSight by 6.6% during the fourth quarter. Invesco Ltd. now owns 20,114 shares of the company’s stock valued at $210,000 after purchasing an additional 1,249 shares in the last quarter. Verition Fund Management LLC boosted its position in shares of RxSight by 4.4% during the fourth quarter. Verition Fund Management LLC now owns 40,613 shares of the company’s stock valued at $423,000 after buying an additional 1,701 shares during the last quarter. Larson Financial Group LLC boosted its position in shares of RxSight by 110.5% during the third quarter. Larson Financial Group LLC now owns 3,979 shares of the company’s stock valued at $36,000 after buying an additional 2,089 shares during the last quarter. Finally, Legal & General Group Plc increased its holdings in RxSight by 5.0% in the 2nd quarter. Legal & General Group Plc now owns 44,574 shares of the company’s stock worth $579,000 after buying an additional 2,121 shares in the last quarter. 78.78% of the stock is owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several research firms have weighed in on RXST. Morgan Stanley boosted their price target on shares of RxSight from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research note on Tuesday, December 2nd. Wells Fargo & Company boosted their target price on RxSight from $9.00 to $10.00 and gave the company an “equal weight” rating in a research note on Thursday, November 6th. William Blair initiated coverage on RxSight in a research report on Friday, January 30th. They set a “market perform” rating on the stock. UBS Group reaffirmed a “neutral” rating on shares of RxSight in a research note on Monday, January 12th. Finally, JPMorgan Chase & Co. increased their price objective on RxSight from $8.00 to $9.00 and gave the company an “underweight” rating in a research note on Thursday, November 6th. Two equities research analysts have rated the stock with a Buy rating, ten have given a Hold rating and three have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Reduce” and a consensus price target of $9.78.

About RxSight

RxSight, Inc is a medical technology company focused on the development and commercialization of advanced intraocular lens (IOL) systems for patients undergoing cataract surgery and lens replacement procedures. The company’s flagship product, the Light Adjustable Lens (LAL), is designed to provide customized vision correction by allowing non‐invasive post‐operative adjustments. Using ultraviolet light, surgeons can fine‐tune the lens power after implantation to achieve optimal visual outcomes, reducing reliance on glasses or contact lenses and enhancing patient satisfaction.

Founded in 2011 and headquartered in Aliso Viejo, California, RxSight has pursued regulatory clearances and market access across multiple regions.